Rapid Screening Method for Antisense Oligonucleotides Against Human Growth Factor Receptor p185erbB-2

Oligonucleotides

Volumn 14, Issue 1, 2004, Pages 1-9

  Rohmann, Anke ^a   Lochmann, Dirk ^a   Weyermann, Jörg ^a   Bertling, Wolf M ^b   Dingermann, Theodor ^a   Zimmer, Andreas ^c  

^a GOETHE UNIVERSITY   (Germany)

^b November AG   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; DEOXYRIBONUCLEASE I; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOFECTIN; LIPOSOME; NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; P185 ERBB2 PROTEIN; PROTEIN P185; SULFUR; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA STRUCTURE; DRUG FORMULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; SCREENING TEST; TUMOR GROWTH; WESTERN BLOTTING;

BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; QUINOLINES; RECEPTOR, ERBB-2;

EID: 1942422088     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/154545704322988003     Document Type: Article

References (27)

1. AGRAWAL, S., TAN, W., CAI, Q., XIE, X., and ZHANG, R. (1997). In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 7, 245-249.
2. ALTSCHUL, S.F., MADDEN, T.L., SCHAFFER, A.A., ZHANG, J., ZHANG, Z., MILLER, W., and LIPMAN, D.J. (1997). Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402.
3. BOGGS, R.T., McGRAW, K.K., CONDON, T., FLOURNOY, S., VILLIET, P., BENNETT, C.F., and MONIA, B.P. (1997). Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7, 461-471.
4. DEFAZIO, A., CHIEW, Y.E., SINI, R.L., JANES, P.W., and SUTHERLAND, R.L. (2000). Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87, 487-498.
5. GUVAKOVA, M.A., YAKUBOV, L.A., VLODAVSKY, I., TONKINSON, J.L., and STEIN, C.A. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
6. HARTMANN, G., WEERATNA, R.D., BALLAS, Z.K., PAYETTE, P., BLACKSWELL, S., SUPARTO, I., RASMUSSEN, W.L., WALDSCMITT, M., SAJUTHI, D., PURCELL, R.H., DAVIDS, H.L., and KRIEG, A.M. (2000). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164, 1617-1624.
7. KERKMANN, M., ROTHENFUSSER, S., HORNUNG, V., TOWAROWSKI, A., WAGNER, M., SARRIS, A., GIESE, T., ENDRES, S., and HARTMANN, G. (2003). Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170, 4465-4474.
8. KRIEG, A.M. (1999). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta 1489, 107-116.
9. KRIEG, A.M., MATSON, S., and FISHER, E. (1996). Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6, 133-139.
10. LASFARGUES, E.Y., COUTINHO, W.G., and REDFIELD, E.S. (1978). Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J. Natl. Cancer Inst. 61, 967-978.
11. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
12. MILLIGAN, J.F., MATTEUCCI, M.D., and MARTIN, J.C. (1993). Current concepts in antisense drug design. J. Med. Chem. 36, 1923-1937.
13. NELLEN, W., and LICHTENSTEIN, C. (1993). What makes an mRNA anti-sense-itive?, Trends Biochem. Sci. 18, 419-423.
14. PEGRAM, M.D., PAULETTI, G., and SLAMON, D.J. (1998). HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77.
15. ROH, H., PIPPIN, J., BOSWELL, C., and DREBIN, J.A. (1998). Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J. Surg. Res. 77, 85-90.
16. ROTHENFUSSER, S., JAHRSDOERFER. B., KRUG, A., ENDRES, S., and HARTMANN, G. (2001). CpG-oligonukleotide: Immuntherapie nach dem Muster der bakteriellen DNA. Deutsches Ärzteblatt 98, A 981-985.
17. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A., and McGUIRE, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
18. STEC, W.J., ZON, G., EGA, W., and STEC, B. (1984). Automated solid-phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxynucleotides. J. Am. Chem. Soc. 106, 6077-6089.
19. STEIN, C.A. (1996). Phosphorothioate antisense oligodeoxynucleotides: Questions of specificity. Trends Biotechnol. 14, 147-149.
20. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261, 1004-1012.
21. TREMPE, G.L. (1976). Human breast cancer in culture. Recent Results Cancer Res. 57, 33-41.
22. TZAHAR, E., and YARDEN, Y. (1998). The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1377, M25-37.
23. UHLMANN, E., RYTE, A., and PEYMAN, A. (1997). Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev. 7, 345-350.
24. VAUGHN, J.P., IGELHART, J.D., DEMIRJI, S., DAVIS, P., BABISS, L.E., CARUTHERS, M.H., and MARKS, J.R. (1995). Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc. Natl. Acad. Sci. USA 92, 8338-8342.
25. VAUGHN, J.P., STEKLER, J., DEMIRJI, S., MILLS, J.K., CARUTHERS, M.H., IGELHART, J.D., and MARKS, J.R. (1996). Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res. 24, 4558-4564.
26. XU, X., HAMOUIYA, F., THOMAS, S.D., BURKE, T.J., GIRVAN, A.C., McGREGOR, W.G., TRENT, J.O., MILLER, D.M., and BATES, P.J. (2001). Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J. Biol. Chem. 276, 43221-43230.
27. ZOBEL, H.P., KREUTER, J., WERNER, D., NOE, C.R., KUMEL, G., and ZIMMER, A. (1997). Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7, 483-493.